Review of Industrial Organization

, Volume 34, Issue 4, pp 373–388 | Cite as

Generic Entry into the Regulated Spanish Pharmaceutical Market

  • Iván Moreno-TorresEmail author
  • Jaume Puig-Junoy
  • Joan-Ramon Borrell


This paper empirically analyses entry by generic firms into the strictly regulated Spanish pharmaceutical market. We estimate a fixed effects negative binomial entry model using a panel of 77 active ingredient markets during the period 1999–2005. The results show that generic entry depends positively on revenues, the age of the market, and the number of previous brand-name competitors, and negatively on the number of generic incumbents. We also find that regulation may drive out competition since, contrary to what policy makers might expect, the system of reference pricing restrains generic entry.


Generic entry Pharmaceutical industry Reference pricing 

JEL Classification

I11 L11 L65 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison P. D., Waterman R. P. (2002) Fixed-effects negative binomial regression models. Sociological Methodology 32: 247–265CrossRefGoogle Scholar
  2. Aronsson T., Bergman M., Rudholm N. (2001) The impact of generic drug competition on brand name market shares—Evidence from micro data. Review of Industrial Organization 19: 425–435CrossRefGoogle Scholar
  3. Bae J. P. (1997) Drug patent expirations and the speed of generic entry. Health Services Research 32: 187–201Google Scholar
  4. Bergman M., Rudholm N. (2003) The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. Journal of Industrial Economics 51: 455–467CrossRefGoogle Scholar
  5. Borrell J. R. (2003) Drug price differentials caused by formularies and price caps. International Journal of the Economics of Business 10: 37–50CrossRefGoogle Scholar
  6. Borrell J. R., Costas A., Nonell R. (2005) Regulation and competition in the market for pharmaceuticals. In: Puig-Junoy J. (eds) The public financing of pharmaceuticals: An economic approach. Edward Elgar, Cheltenham and Northampton, pp 59–83Google Scholar
  7. Brekke K. R., Königbauer I., Straume O. R. (2007) Reference pricing of pharmaceuticals. Journal of Health Economics 26: 613–642CrossRefGoogle Scholar
  8. Cameron A.C., Trivedi P.K. (1998) Regression analysis of count data. Econometric society monograph no. 30. Cambridge University Press, CambridgeGoogle Scholar
  9. Cameron A. C., Trivedi P. K. (2005) Microeconometrics: Methods and applications. Cambridge University Press, CambridgeGoogle Scholar
  10. Costa-Font J., Puig-Junoy J. (2005) The pharmaceutical market regulation in Spain: Is drug cost-containment under question. Journal of Pharmaceuticals Finance, Economics and Policy 13: 33–49CrossRefGoogle Scholar
  11. Danzon P.M., Chao W.L. (2000) Does regulation drive out competition in pharmaceutical markets?. Journal of Law and Economics 43: 311–357CrossRefGoogle Scholar
  12. Danzon, P. M. & Ketcham, J. D. (2004). Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand. Forum for Health Economics & Policy, 7 (Frontiers in Health Policy Research), Article 2. Retrieved from
  13. Daunfeldt S. O., Rudholm N. (2009) Revenues as a proxy for profits: A cautionary note. Applied Economic Letters 16: 679–681CrossRefGoogle Scholar
  14. Daunfeldt S. O., Rudholm N., Bergström F. (2006) Entry into Swedish retail and wholesale trade markets. Review of Industrial Organization 29: 213–225CrossRefGoogle Scholar
  15. Ekelund, M. (2001). Generic entry before and after the introduction of reference prices. In M. Ekelund (Ed.), Competition and innovation in the Swedish pharmaceutical market (Chap. 4, pp. 1–17). Dissertation, Stockholm School of Economics.Google Scholar
  16. Ekelund M., Persson B. (2003) Pharmaceutical pricing in a regulated market. Review of Economics and Statistics 85: 298–306CrossRefGoogle Scholar
  17. Frank R. G., Salkever D. S. (1997) Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6: 75–90CrossRefGoogle Scholar
  18. Grabowski H. G., Vernon J. M. (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35: 331–350CrossRefGoogle Scholar
  19. Hollis A. (2005) How do brands’ ‘own generics’ affect pharmaceutical prices?. Review of Industrial Organization 27: 329–350CrossRefGoogle Scholar
  20. Hong S. H., Shepherd M. D., Scoones D., Wan T. T. H. (2005) Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. Journal of Managed Care Pharmacy 11: 746–754Google Scholar
  21. Hudson J. (2000) Generic take-up in the pharmaceutical market following patent expiry: A multi-country study. International Review of Law and Economics 24: 103–112Google Scholar
  22. Iizuka T. (2009) Generic entry in a regulated pharmaceutical market. Japanese Economic Review 60: 63–81CrossRefGoogle Scholar
  23. IMS Health. (2006a). Health retail drug monitor: Tracking 13 key global pharma markets. London: IMS Health.Google Scholar
  24. IMS Health. (2006b). Estudio del impacto de los medicamentos genéricos en el mercado español. Madrid: IMS Health.Google Scholar
  25. Königbauer I. (2006) Advertising and generic market entry. Journal of Health Economics 26: 286–305CrossRefGoogle Scholar
  26. López-Casasnovas G., Puig-Junoy J. (2000) Review of the literature on reference pricing. Health Policy 54: 87–123CrossRefGoogle Scholar
  27. Magazzini L., Pammolli F., Riccaboni M. (2004) Dynamic competition in pharmaceuticals: Patent expiry, generic penetration, and industry structure. European Journal of Health Economics 5: 175–182Google Scholar
  28. Mestre-Ferrándiz J. (1999) The impact of generic goods in the pharmaceutical industry. Health Economics 8: 599–612CrossRefGoogle Scholar
  29. Puig-Junoy J. (2004a) Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67: 149–165CrossRefGoogle Scholar
  30. Puig-Junoy J. (2004b) Los medicamentos genéricos pagan el precio de ser referencia. Revista de Administración Sanitaria 2: 35–59Google Scholar
  31. Puig-Junoy J. (2007) The impact of generic reference pricing interventions in the statin market. Health Policy 84: 14–29CrossRefGoogle Scholar
  32. Reiffen D., Ward M. E. (2005) Generic drug industry dynamics. Review of Economics and Statistics 87: 37–49CrossRefGoogle Scholar
  33. Reiffen D., Ward M. E. (2007) ‘Branded generics’ as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics 28: 251–265CrossRefGoogle Scholar
  34. Rudholm N. (2001) Entry and the number of firms in the Swedish pharmaceuticals market. Review of Industrial Organization 19: 351–364CrossRefGoogle Scholar
  35. Rudholm N. (2003) Competition and substitutability in the Swedish pharmaceuticals market. Applied Economics 35: 1609–1617CrossRefGoogle Scholar
  36. Saha A., Grabowski H., Birnbaum H., Greenberg P. (2006) Generic competition in the US pharmaceutical industry. International Journal of the Economics of Business 13: 15–38CrossRefGoogle Scholar
  37. Scott Morton F. (1999) Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30: 421–440CrossRefGoogle Scholar
  38. Scott Morton F. (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 18: 1085–1104CrossRefGoogle Scholar
  39. Segura P. (1997) The peculiar patent and generic situation in Spain. Scrip Magazine 58: 23–25Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Iván Moreno-Torres
    • 1
    Email author
  • Jaume Puig-Junoy
    • 1
  • Joan-Ramon Borrell
    • 2
  1. 1.Research Center for Economy and Health, Department of Economics and BusinessUniversitat Pompeu FabraBarcelonaSpain
  2. 2.Research Unit on Public Policeis and Economic Regulation, Departament de Política EconòmicaUniversitat de BarcelonaBarcelonaSpain

Personalised recommendations